Fig. 4: Magnitude and durability of antibody responses induced by sequential IDLV, protein, and DNA +/− protein immunizations.

a Non-human primate immunization regimens with sequential IDLV +/− protein (NHP122 study), protein alone (NHP79 study) and DNA +/− protein (NHP114 study). b ELISA binding of plasma antibodies to CH505 T/F Env at the peak and either 6 or 3 months (for DNA +/− protein) post four immunizations with each vaccine regimen. Binding titers measured as concentration in µg/mL starting at a 1:3000 plasma dilution. Asterisks indicate that a statistically significant difference was detected (p = 0.004 for IDLV-CH505 + protein vs DNA +/− protein and IDLV-CH505 alone vs DNA alone at peak; p = 0.0162 for IDLV-CH505 alone vs DNA + protein at peak; p = 0.0283 for IDLV-CH505 alone vs CH505 protein alone at 6 months; p = 0.0162 for IDLV + protein vs CH505 protein alone at 6 months; p = 0.004 for IDLV-CH505 +/− protein vs DNA alone at the 3 vs 6 months comparison). c Serum neutralization activity against the clade C tier1 virus CH505.w4.3 post four immunizations with each vaccine regimen.